Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson I F, Nilsson J-Å, Kapetanovic M C
Department of Clinical Sciences Lund, Section of Rheumatology, Lund University and Skåne University Hospital , Sweden.
Scand J Rheumatol. 2015;44(4):271-9. doi: 10.3109/03009742.2014.984754. Epub 2015 Feb 6.
To examine the risk of putative pneumococcal infections in adult arthritis patients on different anti-rheumatic drugs immunized with heptavalent pneumococcal conjugate vaccine (Prevenar 7; PCV7) and non-vaccinated individually matched arthritis patients.
All individuals in a cohort of 505 patients with rheumatoid arthritis (RA) or spondylarthropathy (SpA) receiving different anti-rheumatic treatments were immunized with a single dose of PCV7 (exposed group). Of these, 497 patients (RA = 248; SpA = 249) were included. For each vaccinated patient, we identified four reference subjects (n = 1988) from the same geographic area, individually matched for age, gender, and diagnosis. These were considered unexposed to conjugated pneumococcal vaccination. The Skåne Healthcare Register (SHR) was searched for all individuals seeking health care for putative pneumococcal infections occurring 4 years before vaccination and up to 4.5 years after vaccination using ICD-10 diagnostic codes. The following infections were considered as serious cases: pneumonia, other lower respiratory infections, meningitis, sepsis, and septic arthritis. The relative risk (RR) of infection was calculated as the number of events after/number of events before vaccination. Ratios of relative risk (RRRs) were calculated between vaccinated and non-vaccinated groups of patients. A generalized estimating equation (GEE) was used to handle correlated data for several events in the same individual.
Although statistically non-significant, the point estimate of the RRR [0.55, 95% confidence interval (CI) 0.25-1.22] suggested a reduced risk of serious pneumococcal infections in vaccinated patients compared to the unexposed group.
Vaccination with PCV7 tended to reduce the risk of putative serious pneumococcal infections by about 45% compared to non-vaccinated patients in this observational cohort study.
研究接受不同抗风湿药物治疗的成年关节炎患者接种七价肺炎球菌结合疫苗(Prevenar 7;PCV7)后发生疑似肺炎球菌感染的风险,并与未接种疫苗的个体匹配的关节炎患者进行比较。
对一组505例接受不同抗风湿治疗的类风湿关节炎(RA)或脊柱关节炎(SpA)患者全部给予单剂量PCV7免疫(暴露组)。其中,497例患者(RA = 248例;SpA = 249例)被纳入研究。对于每例接种疫苗的患者,我们从同一地理区域确定了4名对照受试者(n = 1988),根据年龄、性别和诊断进行个体匹配。这些对照被视为未接种结合肺炎球菌疫苗。利用ICD - 10诊断编码,在Skåne医疗保健登记处搜索在接种疫苗前4年至接种后4.5年期间因疑似肺炎球菌感染寻求医疗护理的所有个体。以下感染被视为严重病例:肺炎、其他下呼吸道感染、脑膜炎、败血症和化脓性关节炎。感染的相对风险(RR)计算为接种后事件数/接种前事件数。计算接种组和未接种组患者的相对风险比(RRR)。采用广义估计方程(GEE)处理同一患者多个事件的相关数据。
尽管在统计学上无显著差异,但RRR的点估计值[0.55,95%置信区间(CI)0.25 - 1.22]表明,与未暴露组相比,接种疫苗的患者发生严重肺炎球菌感染的风险降低。
在此项观察性队列研究中,与未接种疫苗的患者相比,接种PCV7疫苗倾向于使疑似严重肺炎球菌感染的风险降低约45%。